APLN and early-onset autosomal dominant Alzheimer disease: Overall, these behavioral findings provide important insights into the mechanisms underlying the cognitive-enhancing effects of Apelin-13 and underscore the therapeutic potential of targeting the Nrf2-HO1 pathway for the treatment of Alzheimer’s disease.